Crossmark

Local consolidative therapy extends survival in metastatic NSCLC with oligoresidual disease following first-line immunotherapy, irrespective of PD-L1 expression

Crossref DOI link: https://doi.org/10.1038/s41598-025-20679-2

Published Online: 2025-10-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xie, Wangti

Yan, Maohui

Wen, Fang

Wu, Yu

Cheng, Xiaosan

Hu, Jianbing

Xiao, Jia

Luo, Pan

Su, Yuqi

Ni, Ling

Shan, Rong

Yao, Xiang

Huang, Xianggan

Liu, Tunqian

Liu, Yuan

Weng, Jie
Funding

Funding for this research was provided by:

Clinical Medical Technology Innovation Guidance Project of Hunan Province (2021SK52805)

Clinical Medical Technology Innovation Guidance Project of Hunan Province (2021SK52804)
License Information

Text and Data Mining valid from 2025-10-21

Version of Record valid from 2025-10-21
More Information

Article History

Received: 4 June 2025

Accepted: 16 September 2025

First Online: 21 October 2025

Declarations

:

: The authors declare no competing interests.

Document is current

Any future updates will be listed below